Neuromyelitis Optica Spectrum Disorder Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

March 27 13:52 2020
Neuromyelitis Optica Spectrum Disorder Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

DelveInsight has launched a new report on Neuromyelitis Optica Spectrum Disorder Market Insights, Epidemiology and Market Forecast-2030

DelveInsight’s “Neuromyelitis Optica Spectrum Disorder (NMOSD) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Neuromyelitis Optica Spectrum Disorder (NMOSD), historical and forecasted epidemiology as well as the Neuromyelitis Optica Spectrum Disorder (NMOSD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Neuromyelitis Optica Spectrum Disorder (NMOSD) market report provides current treatment practices, emerging drugs, Neuromyelitis Optica Spectrum Disorder (NMOSD) market share of the individual therapies, current and forecasted Neuromyelitis Optica Spectrum Disorder (NMOSD) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Neuromyelitis Optica Spectrum Disorder (NMOSD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

According to NationalMultipleSclerosisSociety, Neuromyelitis optica (NMO) and NMO Spectrum Disorder (NMOSD), also known as Devic’s disease, is an autoimmune disorder in which immune system cells and antibodies primarily attack the optic nerves and the spinal cord, but may also attack the brain. The damage to the optic nerves produces swelling and inflammation that cause pain and loss of vision; the damage to the spinal cord causes weakness or paralysis in the legs or arms, loss of sensation, and problems with bladder and bowel function. There are two forms of NMO/NMOSD: Relapsing and Monophasic.

 

Request for :- free sample page

Epidemiology

The Neuromyelitis Optica Spectrum Disorder (NMOSD) epidemiology division provide insights about historical and current Neuromyelitis Optica Spectrum Disorder (NMOSD) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Report Key facts:-

1. According to a study “Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan” 2017 conducted by Keiko Tanaka et al, the crude prevalence was 4.1/100,000 (95% confidence interval 2.2–6.9) for NMOSD in northern Japan, with a significantly higher number of female than male patients (female: male 12:2). The positivity for anti-aquaporin-4 antibody was 78.6%, and the mean age at onset was 45.2 years.

2. According to a study “Epidemiology of Neuromyelitis Optica in the World: A Systematic Review and Meta- Analysis” 2015, conducted by RezaVosoughiet al, the prevalence rate of 0.72/100000 (95% CI 0.31–1.42) and minimum combined average annual incidence rate of 0.08/100000 (95% CI 0.03–0.16) indicated that NMO is still an uncommon condition in UK adults

3. According to a study titled, “Nationwide epidemiological study of neuromyelitis optica in Japan” published in Journal of Neurology Neurosurgery & Psychiatry 2018, the prevalence of NMOSD was 3.42 in 100000. The prevalences of definite NMO and NMOSD were significantly higher in Southern Japan than in Northern Japan

“According to a Horizon Scanning Research & Intelligence Centre 2016, NMO/NMOSD affects approximately 0.4 per 10,000 population in the EU, which is equivalent to approximately 2,564 people in the UK.”

 

Drug Chapter

Drug chapter segment of the Neuromyelitis Optica Spectrum Disorder (NMOSD) report encloses the detailed analysis of Neuromyelitis Optica Spectrum Disorder (NMOSD) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Neuromyelitis Optica Spectrum Disorder (NMOSD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Table of contents

1. Key Insights

2. Executive Summary of Neuromyelitis Optica Spectrum Disorder (NMOSD)

3. Competitive Intelligence Analysis for Neuromyelitis Optica Spectrum Disorder (NMOSD)

4. Neuromyelitis Optica Spectrum Disorder (NMOSD): Market Overview at a Glance

4.1. Neuromyelitis Optica Spectrum Disorder (NMOSD) Total Market Share (%) Distribution in 2017

4.2. Neuromyelitis Optica Spectrum Disorder (NMOSD) Total Market Share (%) Distribution in 2030

5. Neuromyelitis Optica Spectrum Disorder (NMOSD): Disease Background and Overview

6. Patient Journey

7. Neuromyelitis Optica Spectrum Disorder (NMOSD) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Neuromyelitis Optica Spectrum Disorder (NMOSD) Treatment and Management

8.2. Neuromyelitis Optica Spectrum Disorder (NMOSD) Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Neuromyelitis Optica Spectrum Disorder (NMOSD) Treatment

11. Marketed Products

12. Emerging Therapies

13. Neuromyelitis Optica Spectrum Disorder (NMOSD): Seven Major Market Analysis

13.1. Key Findings

13.2. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size in 7MM

13.3. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Neuromyelitis Optica Spectrum Disorder (NMOSD)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Neuromyelitis Optica Spectrum Disorder (NMOSD) market
  • To understand the future market competition in the Neuromyelitis Optica Spectrum Disorder (NMOSD) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Neuromyelitis Optica Spectrum Disorder (NMOSD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Neuromyelitis Optica Spectrum Disorder (NMOSD) market
  • To understand the future market competition in the Neuromyelitis Optica Spectrum Disorder (NMOSD) market

Related Reports:-

1. Neuromyelitis Optica Market Insight, Epidemiology and Market Forecast -2030

2. Neuromyelitis Optica Spectrum Disorder (NMOSD) – Epidemiology Forecast to 2030

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/